![Raffaele Colombo: Evoke-01 study of sacituzumab govitecan (SG) did not meet its primary overall survival goal in patients with NSCLC](https://oncodaily.com/pub/uploads/2023/08/Raffaele-Colombo-_-Linkedin-e1699989905831-1280x1128.jpeg)
Photo from Raffaele Colombo/LinkedIn
Jan 24, 2024, 22:30
Raffaele Colombo: Evoke-01 study of sacituzumab govitecan (SG) did not meet its primary overall survival goal in patients with NSCLC
Raffaele Colombo, Principal Scientist at Zymeworks, shared on X:
“Evoke-01 study of sacituzumab govitecan (SG) did not meet its primary overall survival goal in patients with NSCLC
‘A numerical improvement in OS favoring SG was observed’
‘A more than 3-month difference in OS favoring SG was observed in a sub-group'”
Read further.
Source: Raffaele Colombo/X